Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | FABP3 | P05413 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803850 | 0.84 | FABP3 (0.40) | CYP2C9PTGDR2CXCR2HDAC6KDM4E | |
| SCHEMBL6368005 | 0.80 | CXCR2 (0.34) | CYP2C9PTGDR2CXCR2DPP4 | |
| SCHEMBL4713891 | 0.77 | CYP2C9 (0.44) | CYP2C9PTGDR2CXCR2HDAC6KDM4E | |
| SCHEMBL2803782 | 0.77 | CYP2C9 (0.54) | CYP2C9PTGDR2HDAC6KDM4EALDH1A1 | |
| SCHEMBL4712638 | 0.76 | FEN1 (0.42) | CYP2C9PTGDR2CXCR2HDAC6KDM4E | |
| SCHEMBL4715145 | 0.76 | KDM4E (0.44) | CYP2C9PTGDR2HDAC6KDM4EALDH1A1 | |
| SCHEMBL4761013 | 0.75 | PTGDR2 (0.52) | CYP2C9PTGDR2PTGER2 | |
| SCHEMBL2807725 | 0.75 | CYP2C9 (0.55) | CYP2C9PTGDR2HDAC6KDM4E | |
| SCHEMBL14602777 | 0.74 | CYP2C9 (0.43) | CYP2C9PTGDR2CXCR2HDAC6KDM4E | |
| SCHEMBL4718018 | 0.74 | PTGDR2 (0.41) | CYP2C9PTGDR2CXCR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050033052-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-02-10 | — | — | US | disclosed |
| EP-1442043-A1 | CONDENSED PYRIMIDONE DERIVATIVES AS LP-PLA2 INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003042218-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033052-A1 | Novel compounds | LTA4H, PLA2G1B, PLA2G4B | CYP2C9 2344/4885PTGDR2 136/4885CXCR2 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.